e-learning
resources
Vienna 2012
Sunday, 02.09.2012
Effectiveness of therapeutic interventions in primary care
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effectiveness of fixed ICS/LABA combinations in COPD – A population based register linkage study
B. Stallberg, C. Janson, K. Lisspers, G. Johansson, L. Jörgensen, G. Stratelis, G. Telg, K. Larsson (Uppsala, Södertälje, Stockholm, Sweden)
Source:
Annual Congress 2012 - Effectiveness of therapeutic interventions in primary care
Session:
Effectiveness of therapeutic interventions in primary care
Session type:
Thematic Poster Session
Number:
740
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Stallberg, C. Janson, K. Lisspers, G. Johansson, L. Jörgensen, G. Stratelis, G. Telg, K. Larsson (Uppsala, Södertälje, Stockholm, Sweden). Effectiveness of fixed ICS/LABA combinations in COPD – A population based register linkage study. Eur Respir J 2012; 40: Suppl. 56, 740
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
A UK based cost-utility analysis of indacaterol – A once-daily maintenance bronchodilator for patients with COPD
Source: Annual Congress 2012 - Looking at the cost effectiveness of asthma and COPD treatment by novel drugs and improved management
Year: 2012
Interval versus continuous training in individuals with COPD – A systematic review
Source: Annual Congress 2010 - Pulmonary rehabilitation: understanding and developing the intervention
Year: 2010
Evaluation of difficult asthma – a single centre experience
Source: Annual Congress 2009 - Towards improving asthma control
Year: 2009
STIT-1: Evaluation of safety and efficacy of short-time TNI treatment in patients with COPD – First interim analysis
Source: Annual Congress 2010 - Exercise in respiratory diseases and oxygen therapy
Year: 2010
Differences in therapy for stable COPD across Europe – Results of a multicenter study
Source: Annual Congress 2010 - Airway responsiveness, chronic cough and bronchiectasis: a modern approach
Year: 2010
Overdiagnosis of severe asthma – single centre study. Preliminary results
Source: Annual Congress 2009 - Asthma assessment and original therapeutic approaches
Year: 2009
Asthma control and COPD symptom burden: results from a multi-country observational study (SPRINT) in patients using fixed dose combination (FDC) inhalers
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018
Heart rate analysis using multiscale entropy in OSA patients under CPAP treatment – Pilot study
Source: Annual Congress 2011 - Physiology and diagnostic technology in obstructive sleep apnoea
Year: 2011
More than half of patients with COPD in Poland are still smoking, only one third is treated according to GOLD recommendations – Results from PulmoScreen study
Source: Annual Congress 2010 - Therapy and health economics of asthma and COPD
Year: 2010
Limitation of activities in treated patients with asthma may be underestimated – Results of a cohort study
Source: Annual Congress 2011 - Disease management in specific primary care populations
Year: 2011
Efficacy of tiotropium in COPD patients with FEV
1
≥ 60% participating in the UPLIFT trial
Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD
Year: 2010
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with medium-dose ICS/LABA therapy (on GINA step 4) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
Efficacy of mometasone/indacaterol/glycopyrronium (MF/IND/GLY) on lung function and exacerbations in patients with inadequately controlled asthma with high-dose ICS/LABA therapy (on GINA step 5) prior to study entry: Results from IRIDIUM study
Source: Virtual Congress 2021 – Asthma inhalers: new devices and adherence
Year: 2021
COPD therapy based on clinical phenotypes: Baseline data from the Czech multicentre research database of COPD
Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD
Year: 2015
Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study
Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease
Year: 2013
Assessing the therapeutic benefit of a new inhaled QD LABA through population PK-safety & efficacy modelling
Source: Annual Congress 2009 - New bronchodilators
Year: 2009
COPD registers and COPD? – Addition of new computer guided consultation software
Source: Annual Congress 2010 - From diagnosis to disease management in primary care
Year: 2010
A new user cohort study comparing the risk of pneumonia in inhaled corticosteroid (ICS) vs. long-acting bronchodilator (LABD) regimens in COPD
Source: Annual Congress 2013 –Risk factors for COPD and lung function decline
Year: 2013
Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients
Source: International Congress 2016 – Pharmacological management of COPD
Year: 2016
Cost-effectiveness of single- vs multiple-inhaler triple therapy in a UK COPD population: INTREPID trial
Source: Virtual Congress 2021 – Highlights for primary care in 2021
Year: 2021
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept